Studies on a 5 alpha-reductase inhibitor and their therapeutic implications.
D058891:5-alpha Reductase Inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002467:Cell Nucleus / Q000201:enzymology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D009249:NADP / Q000378:metabolism; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011467:Prostate / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000494:pharmacology; D013997:Time Factors
D058891:5-alpha Reductase Inhibitors; D000970:Antineoplastic Agents; D013739:Testosterone; D009249:NADP; D010088:Oxidoreductases